"Global Immuno-oncology Drugs Market Overview:
Global Immuno-oncology Drugs Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Immuno-oncology Drugs Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Immuno-oncology Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Immuno-oncology Drugs Market:
The Immuno-oncology Drugs Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Immuno-oncology Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Immuno-oncology Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Immuno-oncology Drugs market has been segmented into:
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Application, Immuno-oncology Drugs market has been segmented into:
Melanoma
Lung Cancer
Blood Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Immuno-oncology Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Immuno-oncology Drugs market.
Top Key Players Covered in Immuno-oncology Drugs market are:
Coloplast Corp
Bristol Myers Squibb Company
Novartis AG
F. Hoffmann-LA Roche Ltd.
Merck & Co.
Inc.
GSK Plc.
Eli Lilly and Company
Fresenius Kabi AG
Pfizer Inc.
AbbVie Inc.
Genentech Inc.
Sanofi
AstraZeneca
Bayer AG
Bluebird Bio
Inc.
Regeneron Pharmaceuticals
Inc.
Amgen Inc.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Immuno-oncology Drugs Market by Type
4.1 Immuno-oncology Drugs Market Snapshot and Growth Engine
4.2 Immuno-oncology Drugs Market Overview
4.3 Immune Checkpoint Inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Immune Checkpoint Inhibitors: Geographic Segmentation Analysis
4.4 Immune System Modulators
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Immune System Modulators: Geographic Segmentation Analysis
4.5 Cancer Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Cancer Vaccines: Geographic Segmentation Analysis
4.6 Oncolytic Virus
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Oncolytic Virus: Geographic Segmentation Analysis
4.7 Others
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others: Geographic Segmentation Analysis
Chapter 5: Immuno-oncology Drugs Market by Application
5.1 Immuno-oncology Drugs Market Snapshot and Growth Engine
5.2 Immuno-oncology Drugs Market Overview
5.3 Melanoma
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Melanoma: Geographic Segmentation Analysis
5.4 Lung Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Lung Cancer: Geographic Segmentation Analysis
5.5 Blood Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Blood Cancer: Geographic Segmentation Analysis
5.6 Renal Cell Carcinoma
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Renal Cell Carcinoma: Geographic Segmentation Analysis
5.7 Prostate Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Prostate Cancer: Geographic Segmentation Analysis
5.8 Bladder Cancer
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Bladder Cancer: Geographic Segmentation Analysis
5.9 Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Immuno-oncology Drugs Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 COLOPLAST CORP
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BRISTOL MYERS SQUIBB COMPANY
6.4 NOVARTIS AG
6.5 F. HOFFMANN-LA ROCHE LTD.
6.6 MERCK & CO.
6.7 INC.
6.8 GSK PLC.
6.9 ELI LILLY AND COMPANY
6.10 FRESENIUS KABI AG
6.11 PFIZER INC.
6.12 ABBVIE INC.
6.13 GENENTECH INC.
6.14 SANOFI
6.15 ASTRAZENECA
6.16 BAYER AG
6.17 BLUEBIRD BIO
6.18 INC.
6.19 REGENERON PHARMACEUTICALS
6.20 INC.
6.21 AMGEN INC.
Chapter 7: Global Immuno-oncology Drugs Market By Region
7.1 Overview
7.2. North America Immuno-oncology Drugs Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Immune Checkpoint Inhibitors
7.2.4.2 Immune System Modulators
7.2.4.3 Cancer Vaccines
7.2.4.4 Oncolytic Virus
7.2.4.5 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Melanoma
7.2.5.2 Lung Cancer
7.2.5.3 Blood Cancer
7.2.5.4 Renal Cell Carcinoma
7.2.5.5 Prostate Cancer
7.2.5.6 Bladder Cancer
7.2.5.7 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Immuno-oncology Drugs Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Immune Checkpoint Inhibitors
7.3.4.2 Immune System Modulators
7.3.4.3 Cancer Vaccines
7.3.4.4 Oncolytic Virus
7.3.4.5 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Melanoma
7.3.5.2 Lung Cancer
7.3.5.3 Blood Cancer
7.3.5.4 Renal Cell Carcinoma
7.3.5.5 Prostate Cancer
7.3.5.6 Bladder Cancer
7.3.5.7 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Immuno-oncology Drugs Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Immune Checkpoint Inhibitors
7.4.4.2 Immune System Modulators
7.4.4.3 Cancer Vaccines
7.4.4.4 Oncolytic Virus
7.4.4.5 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Melanoma
7.4.5.2 Lung Cancer
7.4.5.3 Blood Cancer
7.4.5.4 Renal Cell Carcinoma
7.4.5.5 Prostate Cancer
7.4.5.6 Bladder Cancer
7.4.5.7 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Immuno-oncology Drugs Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Immune Checkpoint Inhibitors
7.5.4.2 Immune System Modulators
7.5.4.3 Cancer Vaccines
7.5.4.4 Oncolytic Virus
7.5.4.5 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Melanoma
7.5.5.2 Lung Cancer
7.5.5.3 Blood Cancer
7.5.5.4 Renal Cell Carcinoma
7.5.5.5 Prostate Cancer
7.5.5.6 Bladder Cancer
7.5.5.7 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Immuno-oncology Drugs Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Immune Checkpoint Inhibitors
7.6.4.2 Immune System Modulators
7.6.4.3 Cancer Vaccines
7.6.4.4 Oncolytic Virus
7.6.4.5 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Melanoma
7.6.5.2 Lung Cancer
7.6.5.3 Blood Cancer
7.6.5.4 Renal Cell Carcinoma
7.6.5.5 Prostate Cancer
7.6.5.6 Bladder Cancer
7.6.5.7 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Immuno-oncology Drugs Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Immune Checkpoint Inhibitors
7.7.4.2 Immune System Modulators
7.7.4.3 Cancer Vaccines
7.7.4.4 Oncolytic Virus
7.7.4.5 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Melanoma
7.7.5.2 Lung Cancer
7.7.5.3 Blood Cancer
7.7.5.4 Renal Cell Carcinoma
7.7.5.5 Prostate Cancer
7.7.5.6 Bladder Cancer
7.7.5.7 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Immuno-oncology Drugs Scope:
|
Report Data
|
Immuno-oncology Drugs Market
|
|
Immuno-oncology Drugs Market Size in 2025
|
USD XX million
|
|
Immuno-oncology Drugs CAGR 2025 - 2032
|
XX%
|
|
Immuno-oncology Drugs Base Year
|
2024
|
|
Immuno-oncology Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Coloplast Corp, Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., Merck & Co., Inc., GSK Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc., Genentech Inc., Sanofi, AstraZeneca, Bayer AG, Bluebird Bio, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc..
|
|
Key Segments
|
By Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Applications
Melanoma
Lung Cancer
Blood Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Others
|
